布地奈德福莫特罗粉吸入剂联合噻托溴铵粉吸入剂治疗重度支气管哮喘的临床疗效评价

目的探讨布地奈德福莫特罗粉吸入剂联合噻托溴铵粉吸入剂治疗重度支气管哮喘的临床疗效评价。方法选择2016年3月至2017年3月诊断重度支气管哮喘患者76例，随机分为对照组和观察组，每组各38例。对照组给予布地奈德福莫特罗粉吸入剂（160／4．5，2吸／次，2；L／d）治疗观察组在布地奈德福莫特罗粉吸入剂（160／4．5，2吸／次，2次／d）治疗基础上同时给予噻托溴铵粉吸入剂（18μg／次，1次／d）治疗，观察两组哮喘控制测试评分（ACT）、肺功能水平、1年内急性加重次数及药物不良反应。结果经治疗后观察组ACT评分高于对照组（P〈0．05）；经治疗后观察组肺功能指标FEV1、FEV1／FVC（％）、PEF较对照组均有改善（P均〈0．05）；经治疗后观察组较对照组急性发作频次明显下降（P〈0．05）；观察组与对照组不良反应发生率比较差异无统计学意义（P〉0．05）。结论布地奈德福莫特罗粉吸入剂联合噻托溴铵粉吸入剂治疗重度支气管哮喘具有明确的临床疗效，可以改善患者症状评分及肺功能指标，减少急性发作次数，而且具有较好的安全性。

Objective To observe the clinical efficacy of budesonide formoterol combined with tiotropium bromide in the treatment of severe bronchial asthma. Methods A total of 76 patients with severe bronchial asthma selected from our hospital during Mar. 2016- Mar. 2017 were divided into control group and observation group according to random number table, with 38 cases it1 each group. Control group was given Budesonide formoterol powder for inhalation, 2 inhalations each time, bid observation group was additionally given tiotropium bromide powder for inhalation 18 μg, qd, on the basis of control group. Clinical efficacies as well as ACT scores, respiration function indexes and the times of acute attack of asthma before and after treatment, the occurrence of ADR were compared between 2 groups. Results After treatment, ACT scores of observation groups were significantly higher than control group （P〈0.05） . After treatment, respiration function indexes （ FEV1, FEV1 /FVC （ % ） , PEF ） of observation groups were significantly greater than control group （ P〈0.05 ） . After treatment, the times of acute attack of asthma in observation group was significantly less than control group （ P〈0.05 ） . The incidence of ADR in 2 group was no statistical significance compared （ P〉0.05 ） . Conclusions Budesonide formoterol combined with tiotropium bromide in the treatment of severe bronchial asthma can effectively relieve the severity of disease, improve respiration function, reduce the times of acute attack of asthma, and have good therapeutic efficacy and safety.